> top > docs > PMC:7117554 > annotations

PMC:7117554 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 4493-4497 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T2 4498-4502 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T3 6800-6804 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T4 6805-6809 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T5 8397-8401 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T6 8457-8461 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T7 8468-8472 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T8 8639-8648 Body_part denotes stem cell http://purl.org/sig/ont/fma/fma63368
T9 8644-8648 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T10 8906-8916 Body_part denotes basal cell http://purl.org/sig/ont/fma/fma62516
T11 8912-8916 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T12 8940-8948 Body_part denotes prostate http://purl.org/sig/ont/fma/fma9600
T13 9992-10005 Body_part denotes head and neck http://purl.org/sig/ont/fma/fma280881
T14 10178-10184 Body_part denotes breast http://purl.org/sig/ont/fma/fma9601
T15 10958-10969 Body_part denotes spinal cord http://purl.org/sig/ont/fma/fma7647

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 4498-4502 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T2 6805-6809 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T3 8397-8401 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T4 9992-9996 Body_part denotes head http://purl.obolibrary.org/obo/UBERON_0000033
T5 10001-10005 Body_part denotes neck http://purl.obolibrary.org/obo/UBERON_0000974
T6 10178-10184 Body_part denotes breast http://purl.obolibrary.org/obo/UBERON_0000310
T7 10958-10969 Body_part denotes spinal cord http://purl.obolibrary.org/obo/UBERON_0002240

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 0-6 Disease denotes Cancer http://purl.obolibrary.org/obo/MONDO_0004992
T2 8-16 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T3 110-118 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 140-146 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T5 251-257 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T6 281-289 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T7 365-371 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T8 449-459 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T9 465-512 Disease denotes severe acute respiratory syndrome coronavirus 2 http://purl.obolibrary.org/obo/MONDO_0100096
T10 465-498 Disease denotes severe acute respiratory syndrome http://purl.obolibrary.org/obo/MONDO_0005091
T11 514-522 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T12 563-571 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T13 630-638 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T14 698-708 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T15 719-734 Disease denotes viral pneumonia http://purl.obolibrary.org/obo/MONDO_0006012
T16 725-734 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T17 736-771 Disease denotes acute respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0006502
T18 742-771 Disease denotes respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0009971
T19 905-911 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T20 1086-1092 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T21 1116-1124 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T22 1200-1206 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T23 1344-1362 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T24 1604-1610 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T25 1647-1653 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T26 1703-1712 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T27 1722-1728 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T28 1814-1822 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T29 1857-1865 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T30 1902-1908 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T31 1979-1987 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T32 2030-2036 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T33 2163-2171 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T34 2359-2367 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T35 2511-2517 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T36 2757-2763 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T37 2785-2793 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T38 2873-2881 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T39 2927-2933 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T40 3180-3202 Disease denotes cardiovascular disease http://purl.obolibrary.org/obo/MONDO_0004995
T41 3211-3219 Disease denotes diabetes http://purl.obolibrary.org/obo/MONDO_0005015
T42 3236-3255 Disease denotes respiratory disease http://purl.obolibrary.org/obo/MONDO_0005087
T43 3268-3274 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T44 3431-3437 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T45 3536-3544 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T46 3571-3579 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T47 3607-3625 Disease denotes hospital infection http://purl.obolibrary.org/obo/MONDO_0043544
T48 3616-3625 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T49 4483-4509 Disease denotes non-small-cell lung cancer http://purl.obolibrary.org/obo/MONDO_0005233
T50 4498-4509 Disease denotes lung cancer http://purl.obolibrary.org/obo/MONDO_0008903
T51 4503-4509 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T52 4999-5007 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T53 5066-5072 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T54 5280-5288 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T55 5341-5347 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T56 5951-5959 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T57 6783-6788 Disease denotes NSCLC http://purl.obolibrary.org/obo/MONDO_0005233
T58 6790-6816 Disease denotes non-small-cell lung cancer http://purl.obolibrary.org/obo/MONDO_0005233
T59 6805-6816 Disease denotes lung cancer http://purl.obolibrary.org/obo/MONDO_0008903
T60 6810-6816 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T61 6855-6861 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T62 8277-8283 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T63 8523-8539 Disease denotes viral infections http://purl.obolibrary.org/obo/MONDO_0005108
T64 8694-8702 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T65 8852-8858 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T66 8906-8927 Disease denotes basal cell carcinomas http://purl.obolibrary.org/obo/MONDO_0005341
T67 8940-8956 Disease denotes prostate cancers http://purl.obolibrary.org/obo/MONDO_0008315
T68 9394-9400 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T69 9538-9546 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T70 9992-10012 Disease denotes head and neck cancer http://purl.obolibrary.org/obo/MONDO_0002038|http://purl.obolibrary.org/obo/MONDO_0005627
T72 10001-10012 Disease denotes neck cancer http://purl.obolibrary.org/obo/MONDO_0021310
T73 10006-10012 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T74 10115-10132 Disease denotes colorectal cancer http://purl.obolibrary.org/obo/MONDO_0005575
T75 10126-10132 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T76 10178-10191 Disease denotes breast cancer http://purl.obolibrary.org/obo/MONDO_0007254
T77 10185-10191 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T78 11036-11042 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T79 11500-11506 Disease denotes Cancer http://purl.obolibrary.org/obo/MONDO_0004992
T80 11725-11733 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T81 11817-11823 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T82 12269-12277 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T83 12605-12611 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T84 12761-12767 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T85 12786-12794 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T86 12799-12805 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T87 12850-12856 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T88 12857-12865 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T89 13000-13008 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T90 13048-13056 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T91 13143-13151 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T92 13239-13245 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T93 13965-13971 Disease denotes Cancer http://purl.obolibrary.org/obo/MONDO_0004992
T94 14109-14115 Disease denotes Cancer http://purl.obolibrary.org/obo/MONDO_0004992

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 80-81 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T2 157-162 http://purl.obolibrary.org/obo/UBERON_0001456 denotes faces
T3 328-329 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 805-806 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T5 932-937 http://purl.obolibrary.org/obo/UBERON_0001456 denotes faces
T6 1163-1164 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T7 1282-1285 http://purl.obolibrary.org/obo/PR_000001343 denotes aim
T8 1449-1450 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T9 2269-2270 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T10 2740-2742 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T11 3172-3174 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T12 4323-4324 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T13 4493-4497 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T14 4498-4502 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T15 4498-4502 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T16 4769-4774 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T17 4775-4785 http://purl.obolibrary.org/obo/CLO_0001658 denotes activities
T18 5301-5302 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T19 5625-5626 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T20 5683-5688 http://purl.obolibrary.org/obo/CLO_0009985 denotes focus
T21 6582-6583 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T22 6641-6642 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T23 6800-6804 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T24 6805-6809 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T25 6805-6809 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T26 6890-6891 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T27 7339-7340 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T28 7681-7684 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T29 8397-8401 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T30 8397-8401 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T31 8455-8461 http://purl.obolibrary.org/obo/CL_0000084 denotes T cell
T32 8466-8472 http://purl.obolibrary.org/obo/CL_0000236 denotes B cell
T33 8639-8648 http://purl.obolibrary.org/obo/CL_0000034 denotes stem cell
T34 8906-8916 http://purl.obolibrary.org/obo/CL_0000646 denotes basal cell
T35 8961-8962 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T36 9490-9491 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T37 9601-9606 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T38 9748-9749 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T39 9896-9897 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T40 9992-9996 http://purl.obolibrary.org/obo/UBERON_0000033 denotes head
T41 9992-9996 http://www.ebi.ac.uk/efo/EFO_0000964 denotes head
T42 10001-10005 http://www.ebi.ac.uk/efo/EFO_0000967 denotes neck
T43 10178-10184 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
T44 10572-10573 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T45 10695-10696 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T46 10958-10969 http://purl.obolibrary.org/obo/UBERON_0002240 denotes spinal cord
T47 11093-11094 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T48 11115-11116 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T49 11352-11353 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T50 11559-11560 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T51 11743-11746 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T52 12718-12720 http://purl.obolibrary.org/obo/CLO_0001407 denotes 52
T53 13383-13384 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T54 13489-13490 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T55 13606-13607 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T56 13645-13646 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T57 13910-13911 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 4619-4629 Chemical denotes pemetrexed http://purl.obolibrary.org/obo/CHEBI_63616
T2 4660-4670 Chemical denotes pemetrexed http://purl.obolibrary.org/obo/CHEBI_63616
T3 7487-7492 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T4 8369-8373 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T5 10026-10028 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T6 10089-10097 Chemical denotes adjuvant http://purl.obolibrary.org/obo/CHEBI_60809
T7 10193-10195 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T8 14037-14039 Chemical denotes IA http://purl.obolibrary.org/obo/CHEBI_74062

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T1 8523-8539 http://purl.obolibrary.org/obo/GO_0016032 denotes viral infections

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 0-6 Phenotype denotes Cancer http://purl.obolibrary.org/obo/HP_0002664
T2 140-146 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T3 251-257 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T4 365-371 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T5 725-734 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T6 742-762 Phenotype denotes respiratory distress http://purl.obolibrary.org/obo/HP_0002098
T7 905-911 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T8 1086-1092 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T9 1200-1206 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T10 1334-1342 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T11 1367-1375 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T12 1604-1610 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T13 1647-1653 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T14 1722-1728 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T15 1902-1908 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T16 2030-2036 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T17 2511-2517 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T18 2757-2763 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T19 2927-2933 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T20 3180-3202 Phenotype denotes cardiovascular disease http://purl.obolibrary.org/obo/HP_0001626
T21 3268-3274 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T22 3431-3437 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T23 4483-4509 Phenotype denotes non-small-cell lung cancer http://purl.obolibrary.org/obo/HP_0030358
T24 5066-5072 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T25 5341-5347 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T26 6783-6788 Phenotype denotes NSCLC http://purl.obolibrary.org/obo/HP_0030358
T27 6790-6816 Phenotype denotes non-small-cell lung cancer http://purl.obolibrary.org/obo/HP_0030358
T28 6855-6861 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T29 8277-8283 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T30 8516-8539 Phenotype denotes severe viral infections http://purl.obolibrary.org/obo/HP_0031691
T31 8852-8858 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T32 8906-8927 Phenotype denotes basal cell carcinomas http://purl.obolibrary.org/obo/HP_0002671
T33 8940-8956 Phenotype denotes prostate cancers http://purl.obolibrary.org/obo/HP_0012125
T34 9394-9400 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T35 9992-10012 Phenotype denotes head and neck cancer http://purl.obolibrary.org/obo/HP_0012288
T36 10126-10132 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T37 10178-10191 Phenotype denotes breast cancer http://purl.obolibrary.org/obo/HP_0003002
T38 10904-10920 Phenotype denotes acute leukaemias http://purl.obolibrary.org/obo/HP_0002488
T39 10958-10981 Phenotype denotes spinal cord compression http://purl.obolibrary.org/obo/HP_0002176
T40 11036-11042 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T41 11500-11506 Phenotype denotes Cancer http://purl.obolibrary.org/obo/HP_0002664
T42 11817-11823 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T43 12605-12611 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T44 12761-12767 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T45 12799-12805 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T46 12850-12856 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T47 12875-12883 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T48 13086-13094 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T49 13239-13245 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T50 13827-13835 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T51 13965-13971 Phenotype denotes Cancer http://purl.obolibrary.org/obo/HP_0002664
T52 14109-14115 Phenotype denotes Cancer http://purl.obolibrary.org/obo/HP_0002664

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-97 Sentence denotes Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic
T2 99-188 Sentence denotes During the COVID-19 global pandemic, the cancer community faces many difficult questions.
T3 189-306 Sentence denotes We will first discuss safety considerations for patients with cancer requiring treatment in SARS-CoV-2 endemic areas.
T4 307-437 Sentence denotes We will then discuss a general framework for prioritizing cancer care, emphasizing the precautionary principle in decision making.
T5 439-629 Sentence denotes The first infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which leads to coronavirus disease (COVID-19), were reported in Wuhan, China in December 2019 (ref.1).
T6 630-783 Sentence denotes COVID-19 is associated with presentations ranging from asymptomatic infections to severe viral pneumonia, acute respiratory distress syndrome and death1.
T7 784-900 Sentence denotes As of 30 March 2020, a total of 638,146 cases and 30,039 confirmed deaths have been reported across >150 countries2.
T8 901-963 Sentence denotes The cancer community currently faces many difficult questions.
T9 964-1023 Sentence denotes Herein we address the question of treatment prioritization.
T10 1024-1141 Sentence denotes We will first discuss safety considerations for patients with cancer requiring treatment in SARS-CoV-2 endemic areas.
T11 1142-1272 Sentence denotes We will then discuss a general framework for prioritizing cancer care, emphasizing the precautionary principle in decision making.
T12 1273-1515 Sentence denotes While we aim to provide important perspectives from clinical oncology, infectious disease and oncology-value frameworks, this Comment is intended to expand the conversation on a very challenging topic, rather than provide definitive guidance.
T13 1516-1582 Sentence denotes The current pandemic raises two fundamental patient safety issues.
T14 1583-1713 Sentence denotes First, patients with cancer must leave their homes to visit the cancer clinic and thereby possibly expose themselves to infection.
T15 1714-1823 Sentence denotes Second, cancer treatments themselves can predispose patients to the more serious harmful effects of COVID-19.
T16 1824-1909 Sentence denotes Should patients risk exposure to SARS-CoV-2 in order to receive treatment for cancer?
T17 1910-2060 Sentence denotes The available evidence is limited, but suggests that the symptoms of COVID-19 are probably more severe in patients with cancer than for those without.
T18 2061-2268 Sentence denotes Clear evidence exists that older age and higher levels of comorbidity are associated with more severe COVID-19 symptoms and adverse outcomes; this consideration is highly relevant to patients with cancer3,4.
T19 2269-2435 Sentence denotes A report by Liang et al. currently provides the largest series (n = 1,590) describing how COVID-19 outcomes can vary between patients with, and those without cancer4.
T20 2436-2627 Sentence denotes In this model, which included adjustments for age, sex, and comorbidities, cancer is associated with an increased risk of death and/or intensive care unit admission (OR 5.4, 95% CI 1.8–16.2).
T21 2628-2764 Sentence denotes However, interpretation of this finding is limited by the small sample size; the report included data from only 18 patients with cancer.
T22 2765-2944 Sentence denotes In the midst of the COVID-19 pandemic, oncologists will need to weigh the risks of death and morbidity from COVID-19 against the magnitude of benefit of intended cancer therapies.
T23 2945-3091 Sentence denotes Early estimates from China suggest an overall case fatality rate of 2%, increasing to 8% for 70–79 year-olds, and 15% for those ≥80 years of age1.
T24 3092-3171 Sentence denotes Case fatality rates are also markedly higher among patients with comorbidities:
T25 3172-3275 Sentence denotes 11% for cardiovascular disease, 7% for diabetes, 6% for chronic respiratory disease, and 6% for cancer.
T26 3276-3407 Sentence denotes Case fatality rates were far lower outside of Hubei province (0.4% versus 2.9% in Hubei), therefore, these estimates might be high.
T27 3408-3545 Sentence denotes For many patients with cancer, the probable survival benefits of receiving treatment still far outweigh the risks of death from COVID-19.
T28 3546-3643 Sentence denotes The risk of transmitting SARS-CoV-2 can be mitigated through hospital infection control policies.
T29 3644-3917 Sentence denotes We emphasize the importance of meticulous screening of patients and staff (including consideration of symptoms and travel history) before permitting entry into outpatient clinics together with the importance of engineering patient flow to minimize contact between patients.
T30 3918-4042 Sentence denotes These strategies are also important for staff safety, to ensure maximal availability of both clinical and nonclinical staff.
T31 4043-4214 Sentence denotes To reduce the number of clinic visits and the inherent risks, shorter radiotherapy fractionation and conversion of intravenous to oral systemic regimens can be considered.
T32 4215-4339 Sentence denotes The opportunity exists for stopping or reducing frequency of selected maintenance treatments, or those with a long duration.
T33 4340-4680 Sentence denotes For example, at our centre we will be moving from 2-weekly to 4-weekly administration of durvalumab as consolidation therapy for patients with non-small-cell lung cancer (reducing frequency), and recommending the consideration of treatment breaks for those receiving maintenance pemetrexed, or even forgoing maintenance pemetrexed entirely.
T34 4681-4928 Sentence denotes Based on the UNESCO working definition, the precautionary principle dictates that “when human activities may lead to morally unacceptable harm that is scientifically plausible but uncertain, actions shall be taken to avoid or diminish that harm”5.
T35 4929-5093 Sentence denotes This principle should be applied to both our system-level approach to COVID-19 risks, and to treatment recommendations for patients with cancer during the pandemic.
T36 5094-5289 Sentence denotes In balancing these competing priorities, waiting times should be kept as short as reasonably achievable, with careful consideration given to both patient-level and system-level risks of COVID-19.
T37 5290-5387 Sentence denotes We propose a conceptual framework for prioritizing cancer treatment during the pandemic (Fig. 1).
T38 5388-5506 Sentence denotes The examples provided involve radiotherapy and systemic therapy, although the principles are also relevant to surgery.
T39 5507-5662 Sentence denotes Interpretation of this framework will rely heavily on the capacity of locoregional health systems and the position of a given system on the epidemic curve.
T40 5663-5846 Sentence denotes Our discussion will focus on three scenarios: (1) preparedness (with no confirmed cases); (2) moderate health-care resource limitation; and (3) severe health-care resource limitation.
T41 5847-5969 Sentence denotes Fig. 1 Conceptual framework for prioritizing the use of radiotherapy and systemic treatments during the COVID-19 pandemic.
T42 5970-6109 Sentence denotes The lowest and highest priority categories are unevenly spaced to illustrate the concept that prioritization between subgroups is variable.
T43 6110-6191 Sentence denotes The spacing of categories in this diagram is conceptual rather than prescriptive.
T44 6192-6312 Sentence denotes Priority of indications within each category is also variable and subject to the principles discussed in the commentary.
T45 6313-6534 Sentence denotes These include the magnitude of treatment benefit, possible effects of treatment delays or interruptions on outcomes, patient-specific considerations and the availability of staff and resources to safely deliver treatment.
T46 6535-6659 Sentence denotes This overlap implies that some items listed in a lower category could be prioritized over items listed in a higher category.
T47 6660-6782 Sentence denotes Disease indications in each box are meant to serve as illustrative examples and are not intended to be an exhaustive list.
T48 6783-6817 Sentence denotes NSCLC, non-small-cell lung cancer.
T49 6818-7014 Sentence denotes Priority-setting for the delivery of cancer therapies in the context of a pandemic will be strongly influenced by both the magnitude of potential treatment benefit and therapeutic intent (Fig. 1).
T50 7015-7210 Sentence denotes Other considerations include the effects of delays or interruptions on outcomes (if known), patient-specific considerations, and the availability of staff capable of safely delivering treatments.
T51 7211-7452 Sentence denotes The selection of specific indications for which interventions should be postponed is beyond the scope of this Comment; however, a number of published resources are available that quantify the benefits of radiotherapy and systemic therapy6,7.
T52 7453-7553 Sentence denotes We emphasize that even within one group of this hierarchy, prioritization and exceptions will exist.
T53 7554-7646 Sentence denotes Ongoing prioritization requires regular data-driven reassessments in order to minimize harm.
T54 7647-7860 Sentence denotes Importantly, how long the patient has (already) been waiting will change case priority; what constitutes an acceptable delay will vary by priority level, indication and the contextual factors described previously.
T55 7861-8030 Sentence denotes We note that the availability of resources for systemic therapy, radiotherapy and surgery will fluctuate independently to some degree, requiring separate prioritization.
T56 8031-8258 Sentence denotes In addition to the current system environment, the general framework will need to be considered in light of patient-level factors (such as age and/or comorbidities) and patient preferences regarding risks and benefits (Fig. 1).
T57 8259-8329 Sentence denotes Specific risks of cancer therapy might also influence decision making.
T58 8330-8411 Sentence denotes For example, thoracic radiotherapy and drug toxicities might limit lung function.
T59 8412-8661 Sentence denotes Similarly, patients with treatment-related T cell and B cell-mediated immunosuppression might have more severe viral infections, as will patients who are heavily immunosuppressed, such as those who have received haematopoietic stem cell transplants.
T60 8662-8983 Sentence denotes For health systems anticipating COVID-19 cases, but without confirmed cases, continuation of most treatments while considering postponing treatments without an anticipated adverse effect on cancer outcomes (such as treatments for patients with basal cell carcinomas or low-risk prostate cancers) is a reasonable approach.
T61 8984-9107 Sentence denotes Deferring routine follow-up appointments for several months also seems reasonable for most patients in these circumstances.
T62 9108-9218 Sentence denotes Some clinic visits could be replaced with ‘virtual’ assessments conducted by videoconference and/or telephone.
T63 9219-9406 Sentence denotes This approach seeks to balance patient outcomes with system capacity when the anticipated quarantines, isolations and hospitalizations begin to affect the capacity to deliver cancer care.
T64 9407-9514 Sentence denotes These measures also ensure patient safety by reducing the risks of transmission to a vulnerable population.
T65 9515-9775 Sentence denotes When the number of new COVID-19 cases starts to increase, and moderate limitations in human and other health-care resources begin to emerge (such as supply chain interruption), the prioritization of beneficial treatments will become a higher priority (Fig. 1).
T66 9776-9882 Sentence denotes Clear evidence exists that, for certain indications, treatment postponement can adversely affect outcomes.
T67 9883-10055 Sentence denotes For example, a 16% increased risk of death exists for every month of delay of radiotherapy for patients with head and neck cancer (risk ratio (RR) 1.16, 95% CI 1.02–1.32)8.
T68 10056-10272 Sentence denotes Furthermore, delays in receiving adjuvant chemotherapy for colorectal cancer (HR 1.14, 95% CI 1.10–1.17 per 4 weeks)9 and breast cancer (RR 1.08, 95% CI 1.01–1.15 per 4 weeks)10 are associated with inferior survival.
T69 10273-10417 Sentence denotes Although data are currently insufficient, negative effects on outcomes owing to treatment delays seem very plausible for many other indications.
T70 10418-10489 Sentence denotes Thus, the precautionary principle should be applied in decision making.
T71 10490-10722 Sentence denotes Multidisciplinary case conferences (which might be coordinated ‘virtually’ during a pandemic) will remain important venues to prioritize the care of complex patients and to continuously review policies in a rapidly changing context.
T72 10723-10983 Sentence denotes Under the scenario of severe resource constraints, treatment might only be possible in oncological emergencies, including diseases with an imminent risk of early mortality (such as acute leukaemias) or substantial morbidities (such as spinal cord compression).
T73 10984-11154 Sentence denotes If health-system capacity allows, the next level of cancer therapy priorities would be other treatments with a curative intent and a high probability of success (Fig. 1).
T74 11155-11270 Sentence denotes Arrangements might also need to be made to transfer patients to other regions or jurisdictions during the pandemic.
T75 11271-11321 Sentence denotes Triaging should be dynamic, with daily variations.
T76 11322-11591 Sentence denotes On 12 March 2020, ASCO issued a guidance document that further expands on these issues, and other guidance documents are emerging, including from the UK National Health Service, Cancer Care Ontario, ESMO, ASTRO and ESTRO, in addition to a new online resource from ASCO.
T77 11592-11667 Sentence denotes Guidance from regional bodies is important in ensuring consistency in care.
T78 11668-11720 Sentence denotes Open communication between all groups is imperative.
T79 11721-11805 Sentence denotes The COVID-19 pandemic has the potential to overwhelm current health-system capacity.
T80 11806-12064 Sentence denotes Postponing cancer treatments might be associated with some risk, although these risks will need to be considered in light of the magnitude of potential benefits, the impact of waiting times on outcomes and competing patient-level and system-level priorities.
T81 12065-12237 Sentence denotes Throughout the pandemic, supporting our patients’ emotional wellbeing and ensuring that adequate psychosocial support systems are in place will be more important than ever.
T82 12238-12468 Sentence denotes Treatment decisions during the COVID-19 pandemic will rely on the precautionary principle, transparent and evidence-based prioritization of cases for triage, and fluidity in recognizing that local contexts can change very rapidly.
T83 12470-12489 Sentence denotes Further information
T84 12490-12567 Sentence denotes ASCO coronavirus resources: https://www.asco.org/asco-coronavirus-information
T85 12568-12785 Sentence denotes Clinical guide for the management of cancer patients during the coronavirus pandemic: https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/specialty-guide-acute-treatment-cancer-23-march-2020.pdf
T86 12786-12856 Sentence denotes COVID-19 and cancer: https://www.esmo.org/newsroom/covid-19-and-cancer
T87 12857-13047 Sentence denotes COVID-19 clinical oncology frequently asked questions (FAQs): https://www.asco.org/sites/new-www.asco.org/files/content-files/blog-release/pdf/COVID-19-Clinical%20Oncology-FAQs-3-12-2020.pdf
T88 13048-13183 Sentence denotes COVID-19 recommendations to radiation oncology practices: https://www.astro.org/Daily-Practice/COVID-19-Recommendations-and-Information
T89 13184-13365 Sentence denotes Pandemic planning clinical guideline for patients with cancer: https://www.obgyn.utoronto.ca/sites/default/files/oh-cco_pandemic_planning_clinical_guideline_final_2020-03-10_002.pdf
T90 13366-13505 Sentence denotes “Radiotherapy in a time of crisis”, ESTRO Presidents’ statement: https://www.estro.org/About/Newsroom/News/Radiotherapy-in-a-time-of-crisis
T91 13507-13523 Sentence denotes Acknowledgements
T92 13524-13561 Sentence denotes The authors gratefully acknowledge S.
T93 13562-13574 Sentence denotes Berry and M.
T94 13575-13608 Sentence denotes Brundage (Queen’s University), A.
T95 13609-13647 Sentence denotes Detsky (University of Toronto), and A.
T96 13648-13745 Sentence denotes Purushotham (King’s College London) for comments provided on an earlier draft of this manuscript.
T97 13746-13896 Sentence denotes We are also grateful to leaders and our clinical colleagues in the Department of Oncology at Queen’s University for input into the proposed framework.
T98 13897-14045 Sentence denotes T.P.H. holds a research chair provided by the Ontario Institute for Cancer Research through funding provided by the Government of Ontario (#IA-035).
T99 14046-14174 Sentence denotes C.M.B. is supported as the Canada Research Chair in Population Cancer Care through funding provided by the Government of Canada.
T100 14176-14195 Sentence denotes Competing interests
T101 14196-14239 Sentence denotes The authors declare no competing interests.

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
2 0-6 Disease denotes Cancer MESH:D009369
3 8-16 Disease denotes COVID-19 MESH:C000657245
10 237-245 Species denotes patients Tax:9606
11 281-291 Species denotes SARS-CoV-2 Tax:2697049
12 110-118 Disease denotes COVID-19 MESH:C000657245
13 140-146 Disease denotes cancer MESH:D009369
14 251-257 Disease denotes cancer MESH:D009369
15 365-371 Disease denotes cancer MESH:D009369
28 465-512 Species denotes severe acute respiratory syndrome coronavirus 2 Tax:2697049
29 514-524 Species denotes SARS-CoV-2 Tax:2697049
30 449-459 Disease denotes infections MESH:D007239
31 542-561 Disease denotes coronavirus disease MESH:D018352
32 563-571 Disease denotes COVID-19 MESH:C000657245
33 630-638 Disease denotes COVID-19 MESH:C000657245
34 698-708 Disease denotes infections MESH:D007239
35 719-734 Disease denotes viral pneumonia
36 736-771 Disease denotes acute respiratory distress syndrome MESH:D012128
37 776-781 Disease denotes death MESH:D003643
38 851-857 Disease denotes deaths MESH:D003643
39 905-911 Disease denotes cancer MESH:D009369
45 1072-1080 Species denotes patients Tax:9606
46 1116-1126 Species denotes SARS-CoV-2 Tax:2697049
47 1086-1092 Disease denotes cancer MESH:D009369
48 1200-1206 Disease denotes cancer MESH:D009369
49 1344-1362 Disease denotes infectious disease MESH:D003141
67 1560-1567 Species denotes patient Tax:9606
68 1590-1598 Species denotes patients Tax:9606
69 1766-1774 Species denotes patients Tax:9606
70 1831-1839 Species denotes patients Tax:9606
71 1857-1867 Species denotes SARS-CoV-2 Tax:2697049
72 2016-2024 Species denotes patients Tax:9606
73 2244-2252 Species denotes patients Tax:9606
74 1604-1610 Disease denotes cancer MESH:D009369
75 1647-1653 Disease denotes cancer MESH:D009369
76 1703-1712 Disease denotes infection MESH:D007239
77 1722-1728 Disease denotes cancer MESH:D009369
78 1814-1822 Disease denotes COVID-19 MESH:C000657245
79 1902-1908 Disease denotes cancer MESH:D009369
80 1979-1987 Disease denotes COVID-19 MESH:C000657245
81 2030-2036 Disease denotes cancer MESH:D009369
82 2163-2171 Disease denotes COVID-19 MESH:C000657245
83 2258-2264 Disease denotes cancer MESH:D009369
91 2394-2402 Species denotes patients Tax:9606
92 2743-2751 Species denotes patients Tax:9606
93 2359-2367 Disease denotes COVID-19 MESH:C000657245
94 2427-2433 Disease denotes cancer MESH:D009369
95 2511-2517 Disease denotes cancer MESH:D009369
96 2558-2563 Disease denotes death MESH:D003643
97 2757-2763 Disease denotes cancer MESH:D009369
111 3143-3151 Species denotes patients Tax:9606
112 3417-3425 Species denotes patients Tax:9606
113 2785-2793 Disease denotes COVID-19 MESH:C000657245
114 2848-2853 Disease denotes death MESH:D003643
115 2873-2881 Disease denotes COVID-19 MESH:C000657245
116 2927-2933 Disease denotes cancer MESH:D009369
117 3180-3202 Disease denotes cardiovascular disease MESH:D002318
118 3211-3219 Disease denotes diabetes MESH:D003920
119 3236-3255 Disease denotes respiratory disease MESH:D012140
120 3268-3274 Disease denotes cancer MESH:D009369
121 3431-3437 Disease denotes cancer MESH:D009369
122 3525-3530 Disease denotes death MESH:D003643
123 3536-3544 Disease denotes COVID-19 MESH:C000657245
135 3571-3581 Species denotes SARS-CoV-2 Tax:2697049
136 3699-3707 Species denotes patients Tax:9606
137 3804-3814 Species denotes outpatient Tax:9606
138 3867-3874 Species denotes patient Tax:9606
139 3908-3916 Species denotes patients Tax:9606
140 4469-4477 Species denotes patients Tax:9606
141 4429-4439 Chemical denotes durvalumab MESH:C000613593
142 4619-4629 Chemical denotes pemetrexed MESH:D000068437
143 4660-4670 Chemical denotes pemetrexed MESH:D000068437
144 3616-3625 Disease denotes infection MESH:D007239
145 4483-4509 Disease denotes non-small-cell lung cancer MESH:D002289
152 4769-4774 Species denotes human Tax:9606
153 5052-5060 Species denotes patients Tax:9606
154 5240-5247 Species denotes patient Tax:9606
155 4999-5007 Disease denotes COVID-19 MESH:C000657245
156 5066-5072 Disease denotes cancer MESH:D009369
157 5280-5288 Disease denotes COVID-19 MESH:C000657245
159 5951-5959 Disease denotes COVID-19 MESH:C000657245
163 6430-6437 Species denotes patient Tax:9606
164 6783-6788 Disease denotes NSCLC MESH:D002289
165 6805-6816 Disease denotes lung cancer MESH:D008175
167 5341-5347 Disease denotes cancer MESH:D009369
171 7107-7114 Species denotes patient Tax:9606
172 7673-7680 Species denotes patient Tax:9606
173 6855-6861 Disease denotes cancer MESH:D009369
181 8139-8146 Species denotes patient Tax:9606
182 8200-8207 Species denotes patient Tax:9606
183 8423-8431 Species denotes patients Tax:9606
184 8549-8557 Species denotes patients Tax:9606
185 8277-8283 Disease denotes cancer MESH:D009369
186 8369-8384 Disease denotes drug toxicities MESH:D064420
187 8523-8539 Disease denotes viral infections MESH:D001102
197 8892-8900 Species denotes patients Tax:9606
198 9075-9083 Species denotes patients Tax:9606
199 9250-9257 Species denotes patient Tax:9606
200 9434-9441 Species denotes patient Tax:9606
201 8694-8702 Disease denotes COVID-19 MESH:C000657245
202 8852-8858 Disease denotes cancer MESH:D009369
203 8906-8927 Disease denotes basal cell carcinomas MESH:D002280
204 8940-8956 Disease denotes prostate cancers MESH:D011471
205 9394-9400 Disease denotes cancer MESH:D009369
216 10014-10031 Gene denotes risk ratio (RR) 1 Gene:6240
217 9601-9606 Species denotes human Tax:9606
218 9978-9986 Species denotes patients Tax:9606
219 10647-10655 Species denotes patients Tax:9606
220 10193-10197 Gene denotes RR 1 Gene:6240
221 9538-9546 Disease denotes COVID-19 MESH:C000657245
222 9920-9925 Disease denotes death MESH:D003643
223 9992-10012 Disease denotes head and neck cancer MESH:D006258
224 10115-10132 Disease denotes colorectal cancer MESH:D015179
225 10178-10191 Disease denotes breast cancer MESH:D001943
231 11207-11215 Species denotes patients Tax:9606
232 10885-10894 Disease denotes mortality MESH:D003643
233 10904-10920 Disease denotes acute leukaemias MESH:D007938
234 11036-11042 Disease denotes cancer MESH:D009369
235 11500-11506 Disease denotes Cancer MESH:D009369
241 12022-12029 Species denotes patient Tax:9606
242 12105-12113 Species denotes patients Tax:9606
243 11725-11733 Disease denotes COVID-19 MESH:C000657245
244 11817-11823 Disease denotes cancer MESH:D009369
245 12269-12277 Disease denotes COVID-19 MESH:C000657245
248 12495-12506 Species denotes coronavirus Tax:11118
249 12544-12555 Species denotes coronavirus Tax:11118
255 12612-12620 Species denotes patients Tax:9606
256 12632-12643 Species denotes coronavirus Tax:11118
257 12681-12692 Species denotes coronavirus Tax:11118
258 12605-12611 Disease denotes cancer MESH:D009369
259 12761-12767 Disease denotes cancer MESH:D009369
263 12786-12794 Disease denotes COVID-19 MESH:C000657245
264 12799-12805 Disease denotes cancer MESH:D009369
265 12837-12856 Disease denotes covid-19-and-cancer MESH:C000657245
268 12857-12865 Disease denotes COVID-19 MESH:C000657245
269 13000-13008 Disease denotes COVID-19 MESH:C000657245
272 13048-13056 Disease denotes COVID-19 MESH:C000657245
273 13143-13151 Disease denotes COVID-19 MESH:C000657245
276 13225-13233 Species denotes patients Tax:9606
277 13239-13245 Disease denotes cancer MESH:D009369